poisar

Stocks · News reference

Aclaris Therapeutics Announces FDA Fast Track Designation For Modzatinib In Moderate To Severe Lichen Planus; Phase 2b Trial Initiation Expected In Q4 2026

BenzingaAug 6, 2026, 8:37 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 6, 2026, 8:37 PM
Checked
Aug 6, 2026, 8:37 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading